1. Cell Biology
  2. Neuroscience
Download icon

Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain

  1. Shahzad S Khan
  2. Yuriko Sobu
  3. Herschel S Dhekne
  4. Francesca Tonelli
  5. Kerryn Berndsen
  6. Dario R Alessi
  7. Suzanne R Pfeffer  Is a corresponding author
  1. Department of Biochemistry, Stanford University School of Medicine, United States
  2. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, United States
  3. MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, United Kingdom
Research Advance
  • Cited 0
  • Views 931
  • Annotations
Cite this article as: eLife 2021;10:e67900 doi: 10.7554/eLife.67900

Abstract

Activating LRRK2 mutations cause Parkinson’s disease, and pathogenic LRRK2 kinase interferes with ciliogenesis. Previously, we showed that cholinergic interneurons of the dorsal striatum lose their cilia in R1441C LRRK2 mutant mice (Dhekne et al., 2018). Here, we show that cilia loss is seen as early as 10 weeks of age in these mice and also in two other mouse strains carrying the most common human G2019S LRRK2 mutation. Loss of the PPM1H phosphatase that is specific for LRRK2-phosphorylated Rab GTPases yields the same cilia loss phenotype seen in mice expressing pathogenic LRRK2 kinase, strongly supporting a connection between Rab GTPase phosphorylation and cilia loss. Moreover, astrocytes throughout the striatum show a ciliation defect in all LRRK2 and PPM1H mutant models examined. Hedgehog signaling requires cilia, and loss of cilia in LRRK2 mutant rodents correlates with dysregulation of Hedgehog signaling as monitored by in situ hybridization of Gli1 and Gdnf transcripts. Dopaminergic neurons of the substantia nigra secrete a Hedgehog signal that is sensed in the striatum to trigger neuroprotection; our data support a model in which LRRK2 and PPM1H mutant mice show altered responses to critical Hedgehog signals in the nigrostriatal pathway.

Introduction

Mutations in the kinase encoded by the LRRK2 gene represent the predominant cause of familial Parkinson’s disease (PD), a neurodegenerative disorder that results in the loss of dopaminergic neurons in the substantia nigra pars compacta (Poewe et al., 2017; Alessi and Sammler, 2018). LRRK2 encodes a protein kinase and recent work has shown that a subset of Rab GTPases comprise its primary substrates (Steger et al., 2016; Steger et al., 2017). Pathogenic mutations that localize to LRRK2’s ROC domain (e.g. R1441C) and kinase domain (e.g. G2019S) increase its kinase activity in cells (West et al., 2005; Greggio et al., 2006; Jaleel et al., 2007; Ito et al., 2016; Steger et al., 2016), and interactions with other proteins including Rab29 (Kuwahara et al., 2016; Purlyte et al., 2018; Liu et al., 2018; Gomez et al., 2019) and VPS35 can also activate LRRK2 (Linhart et al., 2014; Mir et al., 2018). Reversal of LRRK2 phosphorylation is mediated at least in part by the PPM1H phosphatase that was recently discovered to specifically reverse LRRK2 action on multiple Rab GTPases (Berndsen et al., 2019). In cell culture, loss of PPM1H in wild-type mouse embryonic fibroblast (MEF) cells phenocopies the loss of cilia seen upon expression of pathogenic LRRK2 (Berndsen et al., 2019).

Rab GTPases are master regulators of protein trafficking and carry out their roles by binding to specific partner proteins when the Rabs are GTP-bound (Pfeffer, 2017; Pfeffer, 2018). Phosphorylation of Rab proteins interferes with their abilities to be loaded with GTP by cognate guanine nucleotide exchange factors, a prerequisite for their binding to partner effector proteins (Steger et al., 2016; Steger et al., 2017). This alone would interfere with normal Rab GTPase function. Strikingly, once phosphorylated, Rab GTPases switch their preference and bind to new sets of phospho-specific protein effectors. For Rab8 and Rab10 these include RILPL1, RILPL2, JIP3, and JIP4 proteins (Steger et al., 2017; Dhekne et al., 2018; Waschbüsch et al., 2020) and Myosin Va (Dhekne et al., 2021). The consequences of new phospho-Rab interactions include pathways by which LRRK2 blocks ciliogenesis in cell culture and mouse brain via a process that requires RILPL1 and Rab10 proteins (Steger et al., 2017; Dhekne et al., 2018; Sobu et al., 2021); centriolar cohesion is also altered (Madero-Pérez et al., 2018; Lara Ordónez et al., 2019).

Although later stages of PD resemble those seen in Alzheimer’s disease, PD is first and foremost a movement disorder, and studies to understand it’s underlying causes must focus on understanding why PD is specifically characterized by dopaminergic neuron loss in the substantia nigra. LRRK2 is most highly expressed in immune cells, lung, kidney, and intestine, but it is also present in varying levels throughout the brain (Lis et al., 2018; West et al., 2014; Mandemakers et al., 2012). The striatum is comprised primarily of medium spiny neurons, interneurons and glial cells such as astrocytes. In an important study, Gonzalez-Reyes et al., 2012 showed that dopaminergic neurons in the substantia nigra secrete Sonic Hedgehog (Hh) that is sensed by poorly abundant, cholinergic interneurons in the striatum. Hh is needed for the survival of both these cholinergic target cells and the Hh-producing dopaminergic neurons, despite the fact that only the cholinergic neurons express the PTCH1 Hh receptor. Gonzalez-Reyes et al., 2012 showed further that Hh triggers secretion of glial derived neurotrophic factor (GDNF) from the cholinergic neurons, which provides reciprocal neuroprotection for the dopaminergic neurons of the substantia nigra.

We found previously that the rare, striatal, cholinergic interneurons that would normally sense Hh via their primary cilia are less ciliated in mice carrying the R1441C LRRK2 mutation (Dhekne et al., 2018). In that study, we proposed that cilia loss would decrease the ability of these cells to sense Hh signals. We show here that Hh signaling is indeed impacted by cilia loss in multiple LRRK2 mutant mouse models. Moreover, we show that striatal astrocytes share a broad ciliary deficit that likely impacts synaptic function.

Results

Primary cilia defects in striatal cholinergic interneurons of G2019S LRRK2 mice

We showed previously that cholinergic interneurons that represent about 5% of the neurons in the dorsal striatum of 7 month, R1441C LRRK2 knock-in (KI) mice have fewer primary cilia than their wild type littermates (Dhekne et al., 2018). G2019S LRRK2 is the most common PD-associated mutation in humans, thus it was also important to investigate ciliation in the brains of G2019S LRRK2 mice. G2019S LRRK2 is a hyperactive kinase but less active than R1441C LRRK2 when assayed in cell culture (cf. Steger et al., 2016). The age of the mice was also important: mouse cilia lengthen with age (Arellano et al., 2012) and LRRK2 mutations are incompletely penetrant, making age an important variable in disease onset (Lee et al., 2017; Domingo and Klein, 2018).

Two different mouse lines were examined: 13 month C57BL/6 J mice carrying a genetic knock-in of human LRRK2 G2019S (hereafter referred to as G2019S LRRK2 KI; Steger et al., 2016) and 10 month C57BL/6 J mice overexpressing a BAC transgene encoding human G2019S LRRK2 (hereafter referred to as G2019S LRRK2 BAC Tg; Li et al., 2010). Similar to what we observed previously for 7 month R1441C LRRK2 mice, 13 month G2019S LRRK2 KI mice also displayed a significant loss of primary cilia in choline acetyltransferase (ChAT) interneurons of the dorsal striatum (Figure 1A and B). As before, primary cilia loss was cell-type specific as there was no difference in ciliation or cilia length in the surrounding cells (primarily medium spiny neurons) between mutant and wild-type groups (Figure 1—figure supplement 1). For cholinergic neurons that retained cilia, we detected no significant difference in length between wild type and mutant groups (Figure 1C). Cilia length is important to assess as it is thought to reflect signaling capacity (Guo et al., 2017).

Figure 1 with 1 supplement see all
G2019S LRRK2 striatal cholinergic interneurons have fewer primary cilia.

(A) Confocal images of sections of the dorsal striatum from 13 month wild-type (WT) or G2019S LRRK2 KI mice; Cholinergic Acetyltransferase (ChAT) (green, white outline); Adenylate cyclase 3 (AC3) (magenta, white box), and DAPI (blue). (B) Percentage of ChAT+ neurons containing a cilium. Wild type, light gray; G2019S KI, dark gray as indicated. (C) Quantitation of ChAT+ neuron ciliary length from sections as in A. (D) Confocal images of sections of the dorsal striatum of 10 month WT or G2019S LRRK2 BAC Tg mice; ChAT (green, white outline), AC3 (magenta, white box), and neuron specific nuclear antigen, NeuN (blue). (E) Percentage of G2019S LRRK2 BAC or wild-type ChAT+ interneurons containing a cilium. (F) Quantitation of ChAT+ neuron ciliary length. Scale bar, 10 µm. Significance was determined by t-test; (B) **, p = 0.0016; (E) ***, p = 0.0001. Values represent the data from individual brains, analyzing 4–5 brains per group, 2–3 sections per mouse, and >30 neurons per mouse.

G2019S LRRK2 BAC Tg mice overexpress LRRK2 protein by approximately six-fold (Li et al., 2010) and might be expected to display a more severe phenotype than the G2019S LRRK2 KI mice. In the brains of the 10 month G2019S LRRK2 BAC Tg mice, we also detected a decrease in ciliated cholinergic interneurons (Figure 1D and E), comparable to that seen in the G2019S KI mice; when a primary cilium was present, it was not significantly shorter than wild type control cells (Figure 1F); again, there was no change in ciliation for the surrounding neurons. Taken together, these data show that G2019S LRRK2 mice have primary cilia defects of the same magnitude as previously observed in cholinergic neurons of the dorsal striatum of R1441C LRRK2 KI mice and cultured cells (Steger et al., 2017; Dhekne et al., 2018). Unlike the R1441C mice however, G2019S mice did not show defects in cortical ciliogenesis (Figure 1—figure supplement 1).

Ciliary defects in G2019S striatal astrocytes

Mouse LRRK2 is more highly expressed in astrocytes than neurons (Zhang et al., 2014; http://www.brainrnaseq.org), thus it was important to explore the consequences of LRRK2 mutation on mouse astrocyte ciliation. We used glial fibrillary acidic protein (GFAP) and S100 Calcium Binding Protein B (S100B) to identify astrocytes in the striatum. Astrocytic primary cilia were detected using antibodies specific for ADP Ribosylation Factor Like GTPase 13B (Arl13B) because astrocytes in adult mouse brain do not express detectable amounts of Adenylate Cyclase three (AC3) that we use to stain cilia in neurons (Dhekne et al., 2018; Sterpka and Chen, 2018; Sipos et al., 2018; Kasahara et al., 2014).

Strikingly, we found that GFAP+ G2019S LRRK2 KI and G2019S BAC Tg astrocytes in the dorsal striatum were less likely to have Arl13B+ primary cilia relative to wild type controls (Figure 2). In addition, the remaining GFAP+ cilia in the G2019S BAC Tg astrocytes were very slightly but significantly shorter (Figure 2F). Thus, GFAP+ striatal astrocytes from G2019S LRRK2 KI mice have fewer primary cilia, and striatal astrocytes also have shorter primary cilia upon pathogenic LRRK2 overexpression. Note that astrocyte cilia were shorter overall compared with neuronal cilia (Figures 1C, F, 2C and F), and all cilia were shorter in the BAC Tg mice.

G2019S LRRK2 striatal astrocytes have fewer primary cilia.

(A) Confocal images of sections of the dorsal striatum from 13 month WT or G2019S LRRK2 KI mice; astrocyte marker, Glial fibrillary acidic protein (GFAP) (magenta, white outline), cilia marker, ADP-ribosylation factor-like protein 13B (Arl13B) (green, white box), and DAPI (blue). (B, C) Quantitation of the percentage of astrocytes containing a cilium and astrocyte ciliary length from sections described in A. (D) Confocal images of sections of the dorsal striatum from 10 month G2019S LRRK2 BAC Tg mice, antibody labeled for Glial fibrillary acidic protein (GFAP, magenta, white box), Arl13B (green, white box), and stained with DAPI (blue). (E, F) Quantitation of the percentage of astrocytes containing a cilium and astrocyte ciliary length from sections described in D. Scale bars, 10 µm. Values represent 4–5 brains per group, 2–3 sections per mouse, and >30 astrocytes per mouse. Significance was determined by t-test; B, **, p = 0.0011; E, ** p = 0.0054; F, **** p < 0.0001.

As shown in Figure 3A and B, primary cilia loss in cholinergic interneurons of the dorsal striatum could be detected as early as 10 weeks of age in R1441C LRRK2 KI mice; note that these were the youngest animals analyzed. At this age, fewer striatal cholinergic interneurons have a primary cilium (~40%) in comparison with their non-transgenic littermates (~60%; Figure 3B). Overall neuronal ciliation in the dorsal striatum in 10 week wild type and R1441C mutant groups was slightly lower but similar to the overall values seen previously in a 7 month R1441C LRRK2 KI cohort (~70%; Dhekne et al., 2018).

Two weeks MLi-2 treatment does not alter ciliogenesis in R1441C LRRK2 striatal interneurons or astrocytes.

Mice (8 weeks old) were fed MLi-2 LRRK2 inhibitor-containing chow or control chow for 2 consecutive weeks prior to perfusion and staining. (A) Confocal images of sections of the dorsal striatum from 8 week R1441C LRRK2 KI mice; ChAT (green, white outline); Adenylate cyclase 3 (AC3) (magenta), and DAPI (blue). (B) Quantitation of the percentage of ChAT+ and ChAT- neurons containing a cilium. (C) Percentage of ChAT+ neurons containing a cilium± MLI-2. (D) Quantitation of ChAT+ neuron ciliary length. (E) Confocal images of astrocytes identified by antibodies to GFAP (magenta, white outline), Arl13B (green), and DAPI (blue), ± MLi-2. (F, G) Quantitation of the percentage of total astrocytes (F) or GFAP/S100B+ astrocytes (G) containing a cilium. Scale bars, 10 µm. Significance was determined by t-test. B, *, p = 0.0417.

MLi-2 treatment failed to reverse cilia loss in young R1441C LRRK2 KI Mice

LRRK2 kinase inhibitors are of great interest due to their potential to normalize LRRK2 kinase activity in patients carrying hyperactive LRRK2 mutant forms. Moreover, if ciliation is a relevant disease phenotype, it would be important to know if cilia defects can be corrected in mutant mice treated with a LRRK2 inhibitor. R1441C LRRK2 KI mice were fed the LRRK2 inhibitor, MLi-2, for 2 weeks for phenotypic analysis.

As shown in Figure 3A, C and D, 2 weeks of MLi-2 feeding did not alter the extent of ciliation or cilia length in cholinergic interneurons or astrocytes in the LRRK2 R1441C mice. We also scored primary cilia in two distinct populations of astrocytes – cells that were positive for both GFAP and S100B, and those that were only positive for S100B (Figure 3E–G). Despite 2 weeks of MLi-2 administration, we failed to detect a significant difference in ciliation or cilia length for either population of astrocytes upon treatment. It is important to note that neurons and astrocytes are postmitotic cells with much less dynamic cilia than dividing cells (Sterpka and Chen, 2018); longer times of drug treatment may very well be needed to reveal an effect.

The ability of MLi-2 to block LRRK2-mediated Rab10 phosphorylation in whole, R1441C LRRK2 mutant mouse brains was assessed by western blot (Figure 4A and B). LRRK2 inhibitors decrease LRRK2 phosphorylation at serine 935 (cf. Fell et al., 2015), and pS935-LRRK2 was diminished in wild-type and R1441C LRRK2 brains from mice fed MLi-2 inhibitor, consistent with inhibitor access in this tissue. Rab12 S105 phosphorylation also decreased in wild type (Figure 4C) and mutant (Figure 4A and B) brain. However, levels of pRab10 seemed unchanged (Figure 4A and B) with variability among animals (see also Iannotta et al., 2020). Previous studies have also noted that MLi-2 administration does not markedly reduce pRab10 levels in brain (Kelly et al., 2018; Kalogeropulou et al., 2020; Nirujogi et al., 2021; Kluss et al., 2021). Note that analysis of whole brain in this experiment will not capture the precise status of pRab10 levels in rare cholinergic neurons of the dorsal striatum that show LRRK2 mutation-associated ciliary deficits. Unfortunately, the available anti-phosphoRab10 antibody cannot be used for tissue immunohistochemistry at a single-cell level.

Two weeks of MLi-2 treatment decreases LRRK2 pS935 but does not alter Rab10 phosphorylation in R1441C LRRK2 mouse brain.

(A and B). Littermate- or age-matched LRRK2 R1441C homozygous knock-in mice were fed either a control diet or MLi-2-containing diet for 14 days prior to tissue collection. Two mice from each group were perfused with PBS only; brains collected from these mice were snap frozen in liquid nitrogen and used to monitor inhibition of LRRK2 activity by immunoblotting. (A). 40 μg brain tissue extract was subjected to immunoblot analysis with antibodies specific for the indicated antigens. Duplicate samples were analyzed using the LI-COR Odyssey CLx imaging system. (B). Quantitation of data in A, calculated using Image Studio software (mean ± SD, normalized to control diet-fed animals.) (C). 11 C57BL/6 j wild-type mice received either control diet or diet containing MLi-2, targeted to provide a concentration of 60 mg/kg per day for 14 days. On the last day, 3 mice from the control diet group received 30 mg/kg MLi-2 dissolved in 40 % (w/v) (2-hydroxypropyl)-β-cyclodextrin via subcutaneous injection for 2 hr prior to tissue collection. Forty μg brain tissue extract was subjected to quantitative immunoblotting analysis with the indicated antibodies. Each lane represents a tissue sample from a different animal.

PPM1H deficiency phenocopies LRRK2 mutation

PPM1H phosphatase specifically dephosphorylates LRRK2 Rab GTPase substrates (Berndsen et al., 2019). If LRRK2 action is responsible for loss of cilia in mutant mouse brains, loss of the corresponding phosphatase should yield the same phenotype in that tissue. Figure 5 shows that even heterozygous loss of PPM1H leads to decreased cilia numbers in cholinergic interneurons (Figure 5A and B) and astrocytes (Figure 5C and D) of the dorsal striatum of 5.5 month-old mice. Analysis of 2.5 month-old homozygous PPM1H knockout mice showed a slightly greater defect, despite the fact that fewer cholinergic neurons were ciliated at this age (compare Figure 5B left and right panels). These data demonstrate the importance of high PPM1H levels in wild type brain to counteract LRRK2 action. More importantly, they strongly validate a link between LRRK2-Rab phosphorylation and ciliogenesis in specific brain cell types because loss of the phosphatase shows the same phenotype as the presence of a hyperactive LRRK2 mutation. Immunoblotting showed an appropriate reduction of PPMH protein levels in brain extracts from Ppm1h-/+ and Ppm1h-/- mice, with levels of pRab10 barely changed at least for whole brain tissue from the heterozygous knockout animals with a greater increase for the Ppm1h-/- animals (Figure 5—figure supplement 1).

Figure 5 with 1 supplement see all
PPM1H mutant striatal cholinergic neurons and astrocytes have fewer primary cilia.

(A) Confocal images of sections from 5.5 month Ppm1h-/+ or 2.5 month Ppm1h-/- mice compared with corresponding age-matched WT mice; ChAT (green, white outline); AC3 (magenta, yellow arrowhead), and DAPI (blue). (B) Percentage of ChAT+ neurons of the indicated genotype containing a cilium. Wild type, light gray; Ppm1h mutant, dark gray as indicated. (C) Confocal images of sections of the dorsal striatum from mice described in A and B as indicated; GFAP (magenta), Arl13B (green, yellow arrowhead), and DAPI (blue). (D) Percentage of GFAP+ astrocytes containing a cilium. Wild-type, light gray; Ppm1h-/+ or Ppm1h-/-, dark gray as indicated. Scale bars, 10 µm. Significance was determined by t-test; (B) WT vs Ppm1h-/+; **, p = 0.0018. (C) WT vs Ppm1h-/-; ***, p = 0.0007. (D) WT vs Ppm1h-/+; **, p = 0.0032. WT vs Ppm1h-/-; ***, p = 0.0002. Ppm1h-/+vs Ppm1h-/-; ns, p = 0.3474. Values represent the data from individual brains, analyzing four brains per group, 2–3 sections per mouse, and >30 cells per mouse. Significance was determined either by student’s t-test or by Ordinary one-way ANOVA using Dunnett’s multiple comparisons test. Scale bars, 10 µm.

Sonic Hedgehog signaling is altered in mutant LRRK2 mice

Although Hh signaling is critical during neuronal development, little is known about Hh signaling in the adult brain. As mentioned earlier, striatal ChAT+ interneurons respond to Sonic hedgehog ligands that originate from dopaminergic neurons in the substantia nigra. Sonic hedgehog signaling requires cilia: the transmembrane transducer Smoothened must translocate to the primary cilium to initiate the signaling cascade that results in the expression of the transcription factor Gli1, a direct Hh target gene that serves as a widely-used metric for signaling strength (Corbit et al., 2005; Rohatgi et al., 2007). Thus, primary ciliogenesis is likely critical for proper Hh sensing. We thus examined Hh signaling in LRRK2 mutant animals with pathogenic LRRK2 mutations and associated ciliary defects.

Gli1 transcripts were detected in brain slices using the RNAscope method of fluorescence in situ hybridization. Figure 6A shows detection of Gli1 transcripts in wild type, ChAT+ neurons, which appear as white dots; a negative control hybridization probe yielded no signal under parallel conditions (Figure 6A, bottom row). As expected, ciliated ChAT+ neurons showed higher levels of Gli1 transcripts compared with non-ciliated cells in both mutant and wild-type mice (Figure 6D). Ciliated cholinergic neurons also displayed the highest number of Gli1-positive dots compared with all other cell types in the striatum (monitored by DAPI staining) and compared with non-ciliated cholinergic neurons (Figure 6C and D). This matches well with prior estimates that expression of the Hh receptor PTCH1 is restricted to 6% of total striatal neurons representing all cholinergic and fast spiking interneurons (Gonzalez-Reyes et al., 2012).

Gli1 expression in R1441C LRRK2 dorsal striatal cholinergic Interneurons is cilia dependent and enhanced.

(A) Ten month WT mouse dorsal striatum was subjected to in situ hybridization using a Gli1 probe (gray dots, highlighted by yellow arrowheads) or a negative control probe. ChAT (green, white outline) and DAPI+ nuclei (blue) were detected by immuno- or chemical staining. (B) Ten month WT or R1441C mouse dorsal striatum was labeled as indicated: ChAT (green, white outline), AC3 (magenta, white arrow), Gli1 mRNA (gray dots, yellow arrowheads), DAPI (blue). (C) Average numbers of Gli1 dots per cell for all cell types in the dorsal striatum. Cell numbers were determined by DAPI staining. Values represent the mean ± SEM from 4 WT and 4 R1441C brains each containing >500 DAPI stained nuclei from 30 regions. p = 0.88. (D) Average numbers of Gli1 dots for cholinergic interneurons with or without primary cilia as indicated. Values represent the mean ± SEM from 4 WT and 5 R1441C brains, each containing 9–32 cells. (E) Histogram of the number of Gli1 dots in ciliated cholinergic interneurons from WT or R1441C mice. p = 0.14 (0), 0.054 (1-2),*,0.015 (3-4), 0.79 (5-). Significance was determined by t-test. Arrows indicate primary cilia for ChAT interneurons. Arrowheads indicate Gli1 mRNA dots. Scale bars, 10 µm.

Importantly, the number of Gli1 dots trended higher in ciliated, striatal cholinergic interneurons of R1441C LRRK2 mice (3–4 Gli1-positive dots) compared with wild-type mice (Figure 6D and E). Taken together, these data show that although overall ciliation is decreased, the remaining, ciliated, striatal cholinergic interneurons in R1441C LRRK2 mice transcribe higher quantities of Gli1 in response to R1441C LRRK2 expression. The upregulation of Gli1 transcripts in the remaining ciliated neurons could be due to increased Hh production in the substantia nigra; perhaps the overall decrease in ciliation decreases GDNF production in the striatum, increasing Hh production by subsequently stressed, dopaminergic neurons. Alternatively, the remaining cilia in LRRK2 mutant brains may be structurally intact but functionally altered, leading to increased Gli1 transcript levels. Finally, these data also reveal highly localized Hh signaling in cholinergic neurons in the dorsal striatum compared with their surrounding neighbors, as predicted by the distribution of PTCH1 protein (Gonzalez-Reyes et al., 2012).

Because R1441C LRRK2 striatal astrocytes also have fewer cilia, we determined if their ability to sense or respond to Hh was also altered. Astrocytes express higher levels of PTCH1 receptor than neurons in both rodent and human brain, and thus would be expected to be capable of Hh signaling. Figure 7A and B shows astrocytic Gli1 detection using RNAscope; two classes of astrocytes were scored: those expressing S100B or GFAP. Consistent with the requirement for cilia for canonical Hh signaling, ciliated astrocytes had more Gli1 dots than non-ciliated astrocytes, independent of whether or not the cells expressed pathogenic R1441C LRRK2 (Figure 7C and D): in contrast to ChAT+ interneurons (Figure 6), ciliated and non-ciliated striatal astrocytes from R1441C LRRK2 had similar numbers of Gli1 positive dots relative to their ciliated wild-type controls. Altogether, these data show that striatal astrocytes respond to Hh signaling similarly in R1441C LRRK2 and wild-type mice on an individual cell basis, but overall loss of ciliation due to the LRRK2 mutation appears to lead to an overall decreased striatal astrocytic response.

Gli1 expression in astrocytes is cilia dependent.

(A,B) Ten month R1441C LRRK2 KI mouse dorsal striatum was subjected to in situ hybridization using a Gli1 probe (gray dots, highlighted with yellow arrowheads). Astrocytes were detected with (A) anti-GFAP or (B) anti-S100B (green, white outline); primary cilia were detected with anti-Arl13B (magenta, white arrows). (C,D) Average numbers of Gli1 dots from (C) GFAP and (D) S100B+ astrocytes with or without primary cilia. (E) Relative contribution to total Gli1 dots over GFAP+ astrocytes as a function of their ciliation status. Values represent the mean ± SEM from (C) 4 WT and 3 R1441C brains each containing >35 cells or (D) 3 WT and 3 R1441C brains each containing >21 cells. (C) Ciliated WT vs Unciliated WT: *, p = 0.020, Ciliated R1441C vs Ciliated R1441C: **, p = 0.0032. (D) Ciliated WT vs Unciliated WT: p = 0.12, Ciliated R1441C vs Unciliated R1441C: *, p = 0.017. (E) Ciliated WT vs Unciliated WT: ****, p < 0.0001; Ciliated R1441C vs Unciliated R1441C: ****, p < 0.0001; Unciliated WT vs Unciliated R1441C: ns, p > 0.9999. Significance was determined by unpaired t-test. Arrows indicate primary cilia from GFAP or S100B+ astrocytes. Scale bars, 10 µm.

We next explored if pathogenic LRRK2-associated cilia deficits impact GDNF production by cholinergic neurons of the dorsal striatum. RNAscope fluorescence in situ hybridization for Gdnf transcripts showed that most GDNF was expressed by cholinergic neurons (and not surrounding cells) in the dorsal striatum of wild type mice, consistent with previous reports (Hidalgo-Figueroa et al., 2012; Figure 8). Moreover, Gdnf RNA was preferentially detected in ciliated wild-type cells, consistent with induction by a cilia-mediated pathway such as the Hedgehog pathway (Figure 8A and D). From this result, we anticipated that the increased proportion of non-ciliated cells in LRRK2 mutant animals would lead to an overall deficit in Gdnf transcription. Quantitation of total Gdnf transcripts failed to detect a significant decrease in overall Gdnf transcript signal in 5.5 month-old LRRK2 G2019S mice compared with wild-type animals, under conditions in which we detected an ~40% loss of primary cilia (Figure 8B,C). Gonzalez-Reyes et al., 2012 noted a strong age dependence for loss of GDNF production in the absence of Hh signaling; it is possible that older (12 month old) mice will show a greater defect in Gdnf transcript production. Also note that transcript levels may not correlate with protein production.

Gdnf expression is cilia dependent and dysregulated in LRRK2 G2019S striatum.

(A) 5.5 month WT or LRRK2 G2019S mouse dorsal striatum was subjected to in situ hybridization using a Gdnf probe (white dots) and immunostained as indicated: ChAT (green, white outline), AC3 (red, yellow arrowheads), DAPI (blue). (B) Percent of cells with cilia. (C). Relative level of total Gdnf RNA in ChAT+ neurons as in A. (D) Relative contribution to total Gdnf dots over cholinergic interneurons as a function of their ciliation status. (E) Relative contribution to total Gli1 dots over cholinergic interneurons as a function of their ciliation status in 10 month WT or R1441C mouse dorsal striatum (as in Figure 7). Values represent the mean ± SEM from 4 WT and 4 G2019S brains each containing ≥33 cells. (B) WT vs G2019S, ***, p = 0.0009. (D) Ciliated WT vs Unciliated WT, ****, p < 0.0001. Ciliated WT vs Ciliated G2019S, **, p = 0.0020. Ciliated WT vs Unciliated G2019S; **, p = 0.0040. Unciliated WT vs Ciliated G2019S; **, p = 0.0040. Unciliated WT vs Unciliated G2019S; **, p = 0.0020. (E) Ciliated WT vs. Unciliated WT, ****, p < 0.0001. Unciliated WT vs Ciliated R1441C, **, p = 0.0029. Unciliated WT vs Unciliated R1441C, **, p = 0080; Ciliated WT vs Ciliated R1441C, **, p = 0.0080. Significance was determined either by student’s t-test or by Ordinary one-way ANOVA using Dunnett’s multiple comparisons test. Scale bars, 10 µm.

A completely unexpected result was obtained when we determined the relative contribution of ciliated and non-ciliated neurons in G2019S mutant dorsal striatum to overall Gdnf transcript production (Figure 8D). Unlike their wild-type counterparts, non-ciliated cholinergic neurons in LRRK2 G2019S striatal sections showed significantly higher levels of Gdnf gene expression, consistent with Hedgehog signaling dysregulation. The Hedgehog signaling pathway triggers cilia-dependent processing of the Gli3 protein: Gli3 can be converted into a transcriptional activator or it can be converted into a transcriptional repressor (Bangs and Anderson, 2017; Kong et al., 2019). It is possible that loss of Gli3 repression in non-ciliated LRRK2 mutant neurons increases GDNF production in those cells. Indeed, recent CHIP-Seq experiments identify the Gdnf gene as a Gli3-binding region, at least in the developing mouse limb bud (Lex et al., 2020). Finally, GDNF represses Sonic Hedgehog production by dopaminergic neurons (Gonzalez-Reyes et al., 2012); this may explain the decrease in Gdnf transcripts in ciliated LRRK2 mutant cholinergic neurons relative to wild-type animals, in response to the increased GDNF production by neighboring, non-ciliated LRRK2 mutant cholinergic neurons. Similar analysis of the relative contribution of ciliated cells to Gli1 transcription in R1441C striatum (as in Figure 6) was consistent with a similar trend of dysregulation in unciliated mutant neurons (Figure 8E). Future experiments will seek to isolate these cells for single cell transcriptomic and/or proteomic analyses to determine the underlying basis for the differences observed for Hedgehog pathway components between ciliated and nonciliated mutant neurons.

Phosphorylated Rab10 in astrocyte ciliogenesis

Our previous work in mouse embryonic fibroblasts and patient-derived iPS cells showed the importance of LRRK2-phosphorylated Rab10 and its effector, RILPL1 in primary ciliogenesis blockade (Dhekne et al., 2018). In addition, the fact that PPM1H mutant animals phenocopy hyperactive LRRK2 kinase mutants strongly implicates Rab GTPase phosphorylation in the phenotypes observed. Unfortunately, it was not possible to detect pRab10 directly in mouse brain sections. To explore further the possible contribution of pRab10 to ciliogenesis blockade in astrocytes, we used immunopanning methods (Foo et al., 2011) to obtain primary, poorly dividing astrocytes from G2019S+/- LRRK2 rat brains. Cells are grown in defined, serum-free media containing 5 ng/ml soluble heparin binding EGF-like growth factor (HbEGF) that activates the EGF receptor (Citri and Yarden, 2006) and acts via the EGF receptor in these cells (Foo et al., 2011). Cell density is also relevant as cultured astrocytes secrete other autocrine trophic factors, and ciliogenesis is enhanced in cell culture by increased cell density.

G2019S+/- panned astrocytes showed ~60% ciliation when grown under sparse conditions (Figure 9A and B) as monitored using anti-Arl13B antibodies. Similar to what we have detected in multiple cell types in culture (Steger et al., 2017; Dhekne et al., 2018), pRab10 levels were highest in non-ciliated cells in the absence of the MLi-2 LRRK2 inhibitor (Figure 9B), consistent with a correlation between pRab10 and ciliogenesis.

Immuno-panned primary G2019S LRRK2 astrocytes display increased pRab10.

BAC Transgenic G2019S+/- LRRK2 rat astrocytes were dissected from P5 pups and cultured for 1 week ±200 nM MLi-2. (A). Astrocytes were labeled with anti-GFAP and DAPI (blue, white outline); rabbit-anti-phospho-Rab10 (magenta), and anti-Arl13B (green). The central portions of the bottom row images were enlarged and are shown at the lower right. Top row shows additional examples. (B) Quantitation of pRab10 intensity in ciliated or unciliated G2019S+/- astrocytes as in B. Unciliated G2019S+/- vs Ciliated G2019S+/-; ***, p = 0.0009, Unciliated G2019S+/- vs MLi-2 treated Unciliated G2019S+/-; ****, p < 0.0001; Unciliated G2019S+/- vs Ciliated MLi-2 treated; ****, p < 0.0001; ns = not statistically significant. Significance was determined either by student’s t-test or by Ordinary one-way ANOVA using Dunnett’s multiple comparisons test. Scale bars, 10 µm.

Discussion

Pathogenic LRRK2 activity causes primary cilia loss in striatal cholinergic interneurons in mature R1441C LRRK2 mice (Dhekne et al., 2018). In this study, we show that primary cilia loss is also seen in two distinct G2019S LRRK2 mouse models of the most common human LRRK2 mutation. Moreover, our study reveals that primary cilia loss in cholinergic interneurons can be detected as early as 10 weeks of age, the youngest age we examined. Thus, pathogenic LRRK2 activity causes interneuron primary cilia loss at a relatively early stage and loss is sustained throughout the animal’s lifespan for post-mitotic neurons. Consistent with this conclusion was our finding that mice deficient in the phospho-Rab-specific phosphatase, PPM1H, show the same ciliary defect as mice harboring a pathogenic LRRK2 mutation. This provides strong genetic evidence for the importance of LRRK2 activity in regulating cilia formation, in both LRRK2 wild-type/PPM1H-deficient and LRRK2 mutant animals.

Striatal cholinergic interneurons provide trophic support to dopaminergic neurons via Hh sensing (Gonzalez-Reyes et al., 2012), and primary cilia loss is predicted to perturb the ability of cholinergic neurons to sense Hh ligands as required for this role. Our FISH results support this model by showing that ciliated striatal ChAT+ interneurons express Gli1 transcripts under normal, physiologic conditions, and represent the cell type showing the greatest level of Gli1 expression in the dorsal striatum. In the presence of the pathogenic R1441C LRRK2 mutation, we observed significant elevation of Gli1 transcripts in the smaller number of remaining, ciliated, striatal cholinergic interneurons. One explanation for this increase in Gli1 mRNA is that dopaminergic neurons in the substantia nigra upregulate Hh production due to stress or lack of GDNF signals from the striatum. Cortical neurons have been shown by others to require primary cilia to protect against stresses of ethanol- or ketamine-induced caspase activation and dendritic degeneration (Ishii et al., 2021). Future experiments will seek to monitor changes in Hh production in the substantia nigra that may be associated with LRRK2 mutation.

It was previously reported that loss of Hedgehog production by dopaminergic neurons decreases Gdnf transcripts and protein levels in the striatum in an age-dependent manner, with a 10-fold mRNA decrease seen between 1 and 12 months and a 35% decrease in GDNF protein at 4 months of age (Gonzalez-Reyes et al., 2012). These authors assayed the entire striatum; it is important to note that significant GDNF is produced in the ventral striatum (Barroso-Chinea et al., 2005) and may account for some portion of the changes those authors observed. In our single-cell analyses of cells in the dorsal striatum, we did not detect a significant decrease in Gdnf transcripts at 5 months of age in LRRK2 G2019S striatal cholinergic neurons compared with age matched, wild-type controls. It will be important for us to analyze older mice as these showed a more significant change in the prior study, and to try to carry out GDNF protein analysis specifically in the dorsal striatum.

While transcription of the Hh target genes, Gli1 and Gdnf were entirely cilia-dependent in wild-type cholinergic neurons, this selectivity was lost in G2019S and R1441C animals, where unciliated cells showed a much higher contribution to total Gli1 and Gdnf transcript levels. Both of these genes are Gli3 repressor targets and one would have expected that the absence of a cilium would resemble a condition in which Gli3 repressor is high and target gene expression low. Future work will seek to clarify this unexpected dysregulation of the Hh signaling pathway.

L-dopa-induced dyskinesia is a debilitating side effect of dopamine replacement therapy for Parkinson’s disease. Malave et al., 2021 have shown that Smoothened activation in striatal cholinergic neurons protects mice from L-dopa-induced dyskinesia. These experiments highlight the importance of the Hedgehog signaling pathway for movement coordination regulated by the nigrostriatal circuit, and underscore the importance of studying the consequences of cilia loss associated with LRRK2 mutations since cilia are critical for Hedgehog signaling.

Loss of cilia in astrocytes

For the first time, we show that LRRK2 G2019S striatal astrocytes are also cilia-deficient at 5.5–13 months of age and Gli levels correlate with the presence of primary cilia. The data indicate that fewer striatal astrocytes in LRRK2 G2019S mice are capable of responding to Hh ligands and importantly, the remaining astrocytes that do respond do not compensate for general loss in ciliated cells. How might decreased Hh sensing by astrocytes impact the striatum? Striatal astrocytes functionally interact with distinct networks of medium spiny neurons (Khakh and Deneen, 2019; Martín et al., 2015), and loss of Hh sensing may perturb these interactions. This is relevant because imbalances in medium spiny neuron activity are known to contribute to the slowness and rigidity of movement that is symptomatic of Parkinson’s disease (Zhai et al., 2018).

Chen et al., 2020 recently reported altered organization of glutaminergic AMPA receptors in cultured striatal neurons from LRRK2 G2019S and R1441C mutant mice. This was accompanied by decreased frequency of miniature excitatory post-synaptic currents in brain slices. It is likely that LRRK2-mediated Rab phosphorylation is in some way responsible for these changes; Rab phosphorylation could of course regulate the trafficking of AMPA receptors. It is also possible that in the brain, overall physiological changes are due to loss of cilia from the astrocytes that surround these neurons and support their overall physiology.

Decreased Hh signaling in astrocytes results in the reduction of Kir4.1 potassium channel expression in the cerebellum and neocortex and impairs turnover of dendritic spines, accompanied by an increase in neuronal excitability (Farmer et al., 2016; Hill et al., 2019). Kir4.1 expression is markedly decreased in several neurological disorders (cf. Scholl et al., 2009; Inyushin et al., 2010; Gilliam et al., 2014), including in striatal cells of Huntington’s disease mice (Tong et al., 2014; Dvorzhak et al., 2016). Striatal astrocytes may use Kir4.1 channels to modulate medium spiny neuron synaptic transmission by local buffering of potassium ions, as was shown for other brain regions (Djukic et al., 2007; Sibille et al., 2014). Thus, primary cilia loss from LRRK2 G2019S striatal astrocytes is likely to influence medium spinal neuron circuitry.

Two weeks of LRRK2 MLi-2 inhibitor administration failed to reverse cilia deficits in LRRK2 mutant animals. This may not be surprising as cilia are likely long-lived in post-mitotic neurons and non-reactive astrocytes. Very little is known about the dynamics of cilia in the adult brain; however, data from experiments in which a critical ciliary component, IFT88 was inducibly knocked out in adult brain indicated that 3 months was needed to see the consequences of loss of this ciliary factor (Bowie and Goetz, 2020). Thus, it is possible that longer feeding regimens will reveal a recovery in striatal ciliation. Another puzzle is why pRab10 levels do not change as significantly as pRab12 and LRRK2 pS935 in immunoblots of whole brains of drug-treated animals. It is possible that in the brain, pRab10 is greatly stabilized by strong effector binding. It is important to remember that levels of pRab10 in the very small population of cholinergic neurons of the dorsal striatum may be of major consequence for Hedgehog signaling in the nigrostriatal circuit and MLi-2 sensitivity of pRab10 in these cells would be missed in whole brain immunoblots.

Altogether, these data demonstrate a profound effect of LRRK2 hyperactivation on primary ciliogenesis in a population of cholinergic interneurons that play a key role in motor function and in astrocytes that support medium spiny neuron function in the dorsal striatum. Dysregulation of Hedgehog signaling by cholinergic interneurons and astrocytes of the striatum may contribute to the loss of dopaminergic neurons associated with a disease of aging such as Parkinson’s disease.

Materials and methods

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Genetic reagent(Rattus norvegicus)SA SpragueDawley ratTaconic#SD-MNTac:SD Background
Genetic reagent(Rattus norvegicus)Human LRRK2 G2019S ratTaconic#10,681NTac:SD Background; BAC Transgene
Genetic reagent(Mus musculus)Tg(LRRK2*G2019S)2AMjfJackson Laboratory#018785C57BL/6 Background; BAC Transgene
Genetic reagent(Mus musculus)Constitutive KI Lrrk2tm4.1ArteTaconic#13,940C57BL/6 Background; G2019S KI
Genetic reagent(Mus musculus)B6.Cg-Lrrk2tm1.1Shn/JJackson Laboratory#009346,RRID:IMSR_JAX:009346C57BL/6 Background; R1441C KI
Genetic reagent(Mus musculus)Ppm1h-/- mouseTaconic#TF3142C57BL/6 Background
Antibodyanti-Arl13B(mouse monoclonal)NeuromabN295B/66(1:1000)
Antibodyanti-Adenylate cyclase III(rabbit polyclonal)Santa CruzSC-588(1:100)
Antibodyanti-Adenylate cyclase III(rabbit polyclonal)EnCORRPCA-ACIII(1:10000)
Antibodyanti-NeuN(mouse monoclonal)Proteintech66836–1-IG(1:500)
Antibodyanti-Choline Acetyltransferase(goat polyclonal)MilliporeAB144P-1ML(1:100)
Antibodyanti-GFAP(chicken polyclonal)Novus BiologicalsNBP1-05198(1:2000)
Antibodyanti-GFAP(chicken polyclonal)EnCORCPCA-GFAP(1:2000)
Antibodyanti-S100B(guinea pig polyclonal)Synaptic Systems#287,004(1:200)
Antibodyanti-phospho-Rab10 (Thr73)(rabbit monoclonal)AbcamAB230261(1:1000)
Antibodyanti-Rab10 (mouse monoclonal)Nanotools0680–100/Rab10-605B11(1:1000)
Antibodyanti-phospho-Rab12 (Ser105)(rabbit monoclonal)Abcamab256487(1:1000)
Antibodyanti-Rab12(sheep polyclonal)MRC PPU Reagents and Services, University of DundeeSA227(1:1000)
AntibodyAnti-phospho-LRRK2 (Ser935)(rabbit monoclonal)MRC PPU Reagents and Services, University of DundeeUDD2(1:1000)
AntibodyAnti-LRRK2(mouse monoclonal)Antibodies Inc./NeuroMab75–253(1:1000)
Antibodyanti-PPM1H(sheep polyclonal)MRC PPU Reagents and Services, University of DundeeDA018(1:1000)
Chemical compound, drugMLi-2MRC PPU Reagents and Services, University of Dundee
Commercial assay or kitRNAscopeMultiplexFluorescentReagent Kit v2Advanced Cell Diagnostics#323,100
Commercial assay or kitRNAscope 3-plexNegative ControlProbeAdvanced Cell Diagnostics#320,871
Commercial assay or kitRNAscope Probe- Mm-Gli1Advanced Cell Diagnostics#311,001
Commercial assay or kitRNAscope Probe- Mm-GDNFAdvanced Cell Diagnostics#421,9511:10
Commercial assay or kitOPAL 690 REAGENT PACKAkoya BiosciencesFP1497001KT(1:750)
OtherResearch Diets, Inc.D01060501Untreated diet
OtherResearch Diets, Inc.D01060501 added with 360 mg MLi-2 per kgModified diet
Software, AlgorithmFIJIPMID:29187165RRID:SCR_002285
Software, AlgorithmCellProfilerPMID:29969450RRID:SCR_007358

Key resources

Request a detailed protocol

Primary antibodies and reagents used in this study.

Reagents

MLi-2 LRRK2 inhibitor was synthesized by Natalia Shpiro (MRC Reagents and Services, University of Dundee) and was first described to be a selective LRRK2 inhibitor in previous work (Fell et al., 2015).

Transgenic mice

Request a detailed protocol

All animal studies were performed in accordance with the Animals (Scientific Procedures) Act of 1986 and regulations set by the University of Dundee, the U.K. Home Office, and the Administrative Panel on Laboratory Animal Care at Stanford University. Mice were maintained under specific pathogen-free conditions at the University of Dundee (U.K.); they were multiply housed at an ambient temperature (20–24°C) and humidity (45–55%) and maintained on a 12 hr light/12 hr dark cycle, with rodent diet and water available ad libitum. LRRK2 R1441C knock-in mice backcrossed on a C57BL/6J background, were obtained from the Jackson laboratory (Stock number: 009346). LRRK2 G2019S knock-in and PPM1H knock-out mice backcrossed on a C57BL/6J background, were obtained from Taconic (Model 13,940 and TF3142, respectively). G2019S BAC transgenic brain sections from 10 month mice were a gift from Aaron Gitler at Stanford (Li et al., 2010). Mouse genotyping was performed by PCR using genomic DNA isolated from tail clips or ear biopsies. For the experiment shown in Figure 5, Figure 5—figure supplement 1, 63–83 day old mice of the indicated genotypes were injected subcutaneously with vehicle [40 % (w/v) (2-hydroxypropyl)-β-cyclodextrin (Sigma–Aldrich #332607)] or MLi-2 dissolved in the vehicle at a 30 mg/kg final dose. Mice were euthanized by cervical dislocation 2 hr following treatment and the collected tissues were rapidly snap frozen in liquid nitrogen.

Mouse brain processing

Request a detailed protocol

Homozygous LRRK2-mutant (R1441C or G2019S of ages indicated) or heterozygous Ppm1h-/+ mice (164 days old) and age-matched wild type controls were fixed by transcardial perfusion using 4% paraformaldehyde (PFA) in PBS as described in Khan et al., 2020. Next, whole brain tissue was extracted, post-fixed in 4% PFA for 24 hr and then immersed in 30% (w/v) sucrose in PBS until the tissue settled to the bottom of the tube (~48 hr). LRRK2 R1441C KI, LRRK2 G2019S KI and Ppm1h-/+ brains were harvested in Dundee and sent with identities blinded until analysis was completed. Prior to cryosectioning, brains were embedded in cubed-shaped plastic blocks with OCT (BioTek, USA) and stored at −80 °C. OCT blocks were allowed to reach −20 °C for ease of sectioning. The brains were oriented to cut sagittal or coronal sections on a cryotome (Leica CM3050S, Germany) at 16–25 µm thickness and positioned onto SuperFrost plus tissue slides (Thermo Fisher, USA).

In-diet MLi-2 administration to wild-type mice (Pilot study) and LRRK2 R1441C KI mice

Request a detailed protocol

For the experiment shown in Figure 4, 11 C57BL/6J wild-type mice were allowed to acclimate to the control rodent diet (Research Diets D01060501; Research Diets, New Brunswick, NJ) for 14 days before being placed on study. On day 1 of the study, one group (4 mice) received modified rodent diet (Research Diets D01060501) containing MLi-2 and formulated by Research Diets to provide a concentration of 60 mg/kg per day on the basis of an average food intake of 5 g/day for 14 days; the other group (7 mice) received untreated diet (Research Diets D01060501) for 14 days and served as the control group. The dose of MLi-2 and the length of the in-diet treatment used for this study were based on Fell et al., 2015. Bodyweight and food intake were assessed twice weekly. On the last day of the study, 3 mice from the control diet group received 30 mg/kg MLi-2 dissolved in 40% (w/v) (2-hydroxypropyl)- β-cyclodextrin via subcutaneous injection for 2 hr prior to tissue collection. All mice were euthanized by cervical dislocation and the collected tissues were rapidly snap frozen in liquid nitrogen and brain samples used for quantitative immunoblotting analysis of phospho-Ser935 LRRK2 and phospho-Ser105 Rab12 as a readout of LRRK2 activity.

For the experiments described in Figure 3C–G, littermate or age-matched male and female LRRK2 R1441C homozygous knock-in mice at 10 weeks of age were used. Mice were allowed to acclimate to the control rodent diet for 14 days as described above before being placed on study. On day 1 of the study, one group (7 mice) received a modified rodent diet targeted to provide a concentration of 60 mg/kg per day on the basis of an average food intake of 5 g/day; the other group (7 mice) received an untreated diet and served as the control group. Bodyweight and food intake were assessed twice weekly. On day 15, mice were terminally anesthetized and brains harvested and fixed as described above. For immunoblotting analysis to confirm LRRK2 inhibition, brains were snap frozen in liquid nitrogen from mice that were terminally anesthetized and perfused by injection of PBS into the left cardiac ventricle (2 mice from each group).

Preparation of mouse tissue lysates for immunoblotting analysis

Request a detailed protocol

Snap frozen tissues were weighed and quickly thawed on ice in a 10-fold volume excess of ice-cold lysis buffer containing 50 mM Tris–HCl pH 7.4, 1 mM EGTA, 10 mM 2-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 270 mM sucrose, supplemented with 1 μg/ml microcystin-LR, 1 mM sodium orthovanadate, complete EDTA-free protease inhibitor cocktail (Roche), and 1% (v/v) Triton X-100. Tissues were homogenized using a POLYTRON homogenizer (KINEMATICA), employing three rounds of 10 s homogenization with 10 s intervals on ice. Lysates were clarified by centrifugation at 20,800 g for 30 min at 4°C and supernatant was collected for subsequent protein quantification by Bradford assay and immunoblot analysis.

Quantitative immunoblotting analysis

Request a detailed protocol

40 μg of brain extracts were loaded onto a NuPAGE 4–12% Bis–Tris Midi Gel (Thermo Fisher Scientific, Cat# WG1402BOX) and electrophoresed at 130 V for 2 hr with NuPAGE MOPS SDS running buffer (Thermo Fisher Scientific, Cat# NP0001-02). Proteins were then electrophoretically transferred onto a nitrocellulose membrane (GE Healthcare, Amersham Protran Supported 0.45 µm NC) at 100 V for 90 min on ice in transfer buffer (48 mM Tris–HCl and 39 mM glycine supplemented with 20% (v/v) methanol). The transferred membrane was blocked with 5% (w/v) skim milk powder dissolved in TBS-T (50 mM Tris base, 150 mM sodium chloride (NaCl), 0.1% (v/v) Tween 20) at room temperature (RT) for 30 min and incubated overnight at 4°C in primary antibodies diluted in 5% (w/v) BSA in TBS-T. After incubation with primary antibodies, membranes were washed three times for 5 min with TBS-T and incubated with near-infrared fluorescent dye-labelled secondary antibodies (diluted to 1:20,000) for 1 hr at RT. Thereafter, membranes were extensively washed with TBS-T and protein bands were acquired via near-infrared fluorescent detection using the Odyssey CLx imaging system and the signal intensity quantified using Image Studio software.

Fluorescence in situ hybridization (FISH)

Request a detailed protocol

Wild-type (WT) and R1441C LRRK2 KI 10 month mouse brains were sliced coronally at 25 µm thickness. RNAscope Multiplex Fluorescent Detection Kit v2 (Advanced Cell Diagnostics) was carried out according to the manufacturer using RNAscope 3-plex Negative Control Probe (#320871) or Mm-Gli1 (#311001). Opal 690 (Akoya Biosciences) was used for fluorescent visualization of hybridized probes. Then, brain slices were blocked with 0.1% BSA and 10% donkey serum in TBS (Tris buffered saline) containing 0.1% Triton X-100 for 30 min followed by incubation with primary antibody in TBS +0.1% BSA and 1% DMSO overnight at 4 °C. Secondary antibody was also diluted in TBS +0.1% BSA and 1% Triton X-100 for 30 min and then added for 2 hr at RT. Sections were mounted with ProLong Gold Antifade Mountant with DAPI and glass coverslips. For Gdnf RNA experiments, WT and G2019S LRRK2 KI 5 month mouse sections were sliced coronally at 25 µm thickness. RNAscope Multiplex Fluorescent Detection was performed as above using Mm Gdnf (#421951) diluted 1:10 in dilution buffer (6 x saline-sodium citrate buffer (SSC), 0.2% lithium dodecylsulfate (Research Products International; #RPI-L26200), and 20% Calbiochem OmniPur Formamide (#75-12-7)).

Immunofluorescence staining and microscopy

Request a detailed protocol

Brain primary cilia detection and analyses were performed as previously described (Khan et al., 2020). Briefly, frozen slides were thawed at RT for 10 min then gently washed with PBS for 5 min. Sections were permeabilized with 0.1% Triton X-100 in PBS at RT for 15 min. Sections were blocked with 2% BSA in PBS for 2 hr at RT and were then incubated overnight at 4°C with primary antibodies. The following day, sections were incubated with secondary antibodies at RT for 2 hr. Donkey highly cross-absorbed H + L secondary antibodies (Life Technologies) conjugated to Alexa 488, Alexa 568 or Alexa 647 were used at a 1:1000 dilution. Stained tissues were overlayed with Mowiol and a glass coverslip. All antibody dilutions for tissue staining included 1% DMSO to help antibody penetration. All images were obtained using a spinning disk confocal microscope (Yokogawa) with an electron multiplying charge coupled device (EMCCD) camera (Andor, UK) and a 100 × 1.4 NA oil immersion objective. All image visualizations and analyses were performed using Fiji (RRID:SCR_002285; Rueden et al., 2017). Cholinergic neurons in the dorsal striatal region were identified in the caudate putamen of sagittal or coronal sections that were reactive for both choline acetyltransferase and the pan neuronal marker, NeuN. Dorsal striatal astrocytes were defined as GFAP+ and/or S100B+ cells in the caudate putamen.

Astrocyte immune-panning and microscopy

Request a detailed protocol

Rat Astrocyte Immune-panning was performed as previously described (Foo et al., 2011; Dhekne et al., 2018). Cells on coverslips were fixed with 3.5% PFA for 15 min at RT. The cells were then subjected to three washes with PBS for 5 min each. To permeabilize, samples were incubated with PBS containing 0.1% Saponin for 15 min. All subsequent steps contained 0.05% Saponin unless otherwise specified. Samples were again washed three times with PBS then incubated in blocking solution (PBS containing 2% BSA) for 1 hr at RT. Afterwards, the cells were incubated in blocking solution containing primary antibodies for 1 hr at RT (EnCOR Chicken-anti-GFAP at 1:2000, Abcam Rabbit-anti-pRab10 at 1:1000, Neuromab Mouse-anti-Arl13B at 1:2000). Cells were then washed three times with blocking solution, then incubated for 1 hr at RT with blocking solution containing DAPI and donkey-anti alexa fluor secondary antibodies. Coverslips were then rinsed without saponin in PBS two times, in ddH2O once, and then mounted with mowiol. All image visualizations and analyses were performed using Fiji (RRID:SCR_002285). Maximum intensity projections, background subtraction, and pRab10 integrated intensity measurements were obtained using CellProfiler (RRID:SCR_007358; McQuin et al., 2018).

Statistics

Graphs were made using Graphpad Prism six software (GraphPad Prism, RRID:SCR_002798). Error bars indicate SEM. Unless otherwise specified, a Student’s T-test was used to test significance. Brains were harvested in Dundee and analyzed at Stanford; identities were blinded for unbiased analyses. RNA hybridization was quantified using CellProfiler (RRID:SCR_007358; McQuin et al., 2018).

Data availability

All primary data associated with each figure has been deposited in the Dryad repository and can be found at https://doi.org/10.5061/dryad.76hdr7sxx.

The following data sets were generated
    1. Pfeffer SR
    (2021) Dryad Digital Repository
    Data from: Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain.
    https://doi.org/10.5061/dryad.76hdr7sxx

References

    1. Pfeffer SR
    (2018) LRRK2 and Rab GTPases
    Biochemical Society Transactions 46:1707–1712.
    https://doi.org/10.1042/BST20180470

Decision letter

  1. Wade Harper
    Reviewing Editor; Harvard Medical School, United States
  2. Philip A Cole
    Senior Editor; Harvard Medical School, United States
  3. Peter S McPherson
    Reviewer; Montreal Neurological Institute, McGill University, Canada

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

This is an interesting follow-up to a paper recently published in eLife reporting the discovery of a phosphatase (PPM1H) that can remove phosphate from sites of modification in Rabs that are phosphorylated by LRRK2. This new work demonstrates that LRRK2 mutants are incapable of building cilia in cholinergic interneurons of the dorsal striatum. Interestingly, this phenotype is recapitulated in the PPM1H mouse mutant, clearly implicating LRRK2-dependent phosphorylation of specific Rabs as critical for the formation/maintenance of cilia. As expected, this cilia phenotype correlates with a defect in hedgehog signaling in vivo. Because LRRK2 mutants have increased levels of Rab phosphorylation, as do PPM1H mutants, this data fits nicely with the idea that the status of Rab phosphorylation is having input on cilia.

Decision letter after peer review:

Thank you for resubmitting your work entitled "Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain" for further consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Peter McPherson (Reviewer #2)

The manuscript has many strengths and the reviewers are generally quite positive but there are some remaining issues that need to be addressed, as outlined below:

1. It would make the case a bit stronger if the authors could look at the transcript levels of GDNF from the same RNA samples they used to analyze Gli1.

2. The work is of immense importance and experiments were well performed. However, more clarification in the text would be required if not more experiments, on the possible effect(s) of elevated levels of Gli1 transcript in the striatum. Additional work would allow the authors to get a sense of whether/how the changes in Gli levels that they report for the ciliated vs non ciliated translate to changes at the population level for each of the cell types. The authors suggest how they think it works, but it would be nice to actually show it. For example do the cholinergic neurons overall have reduced Hh output despite the fact that the cells that remain ciliated increase their response? This seems important in terms of understanding what is happening at the tissue level.

3. Clarify the timing of the LRRK2 inhibitor experiments and why there was, and especially why there is not much of a change in Rab10 phosphorylation. Try to strengthen the link between Rab10 phosphorylation and reduced cilia.

In order to facilitate the revision, we have included all of the comments from the reviewers for a perspective but you should focus on the list above. We look forward to seeing your revised paper.

Reviewer #1:

This is an interesting follow-up to a paper recently published in eLife reporting the discovery of a phosphatase (PPM1H) that can remove phosphate from sites of modification in Rabs that are phosphorylated by LRRK2. This new work demonstrates that LRRK2 mutants are incapable of building cilia in cholinergic interneurons of the dorsal striatum. Interestingly, this phenotype is recapitulated in the PPM1H mouse mutant, clearly implicating LRRK2-dependent phosphorylation of specific Rabs as critical for the formation/maintenance of cilia. As expected, this cilia phenotype correlates with a defect in hedgehog signaling in vivo. Because LRRK2 mutants have increased levels of Rab phosphorylation, as do PPM1H mutants, this data fits nicely with the idea that the status of Rab phosphorylation is having input on cilia.

The primary phenotypes observed reflect a reduction (generally ~50%) in cilia number for the various LRRK2 and PPM1H mutants examined in both interneurons and astrocytes. In cells that maintained cilia, the length of the cilia were largely unchanged. This raises the question about what is different among the cells that did and did not generate a cilia. But addressing this question is likely beyond the scope of this paper.

Overall, the data as far as it goes is well presented and controlled. Replicate experiments are included at every stage, indicating the robustness of the results.

So in my view, this paper fits well into the Research Advances category in that it provides a strong indication that PPM1H functions biologically in the same pathway as LRRK2 mutation.

Reviewer #2:

This work builds on Dhekne et al., 2018, demonstrating decreased ciliation of cholinergic neurons in the striatum of LRRK2 R1441C mice. The findings cause the authors to speculate that such decreased ciliation phenotype might lead to a decrease in sonic hedgehog (Hh) response, which might further impact a neuro-protective circuit that supports dopaminergic neurons.

In this study, the authors provide evidence to support the idea of reduced Hh response and report the following important findings:

1) G2019S LRRK2 mice also show loss of cilia in striatal cholinergic interneurons. This finding was also supported by the data showing loss of primary cilia in the phospho-Rab-specific phosphatase, PPM1H deficient mice. As PPM1H specifically dephosphorylates LRRK2 substrates, collectively it strengthens the fact that the phenotype is caused by LRRK2 mutations (both R1441C and G2019S).

2) Although the number of cholinergic cells showing cilia are less, Gli1 transcripts were found to be elevated in those smaller number of cells. A similar pattern was noted in astrocytes. The authors suggest that the overall loss of ciliation due to the LRRK2 mutation will lead to an overall decrease in striatal astrocytic Hh response.

3) In addition, striatal astrocytes were cilia-deficient, leading to new hypotheses to be tested in future in terms of the current knowledge of how astrocytes support neurons with respect to Parkinson's model.

While this study tests an important idea of how defect in ciliogenesis could lead to dopaminergic neuron loss based on the current knowledge of circuits between dopaminergic neurons in the substantia nigra and cholinergic interneurons in the striatum (Gonzalez-Reyes et al., (2012)), it has a missing component that should be addressed in order to establish this model:

It would be important to measure GDNF expression in the striatum. As the authors speculate that there is an overall decrease in Hh response due to less cilia, this statement will carry more weight if the authors show that there is an inhibition of GDNF expression. Ideally this would be done by measuring secreted GDNF. However, this may be technically very demanding. Alternatively, the authors could examine GDNF transcripts. Altered GDNF transcript/expression/release is more likely to cause damage to the dopaminergic neurons. As there is an elevated level of Gli1 transcripts in a smaller number of ciliated cells (cholinergic) in R1441C mice, it raises concerns about how much of DA loss might happen when there is an elevated level of Gli1. Addressing the question on GDNF could solve the issue.

It would really build the study if you could examine GDNF expression, as is done in figure 6B of the Gonzalez-Reyes et al., (2012) manuscript. I do understand if this is too technically demanding. Alternatively, one could examine GDNF transcripts.

Are there humans with PPM1H variants? NCBI's Clinvar database is a very good site to explore this.

"Rab12 S105 phosphorylation also decreased in wild type (Figure 4C) and mutant (Figure 4A, B) brain (Figure 4). However, levels of pRab10 seemed unchanged (Figure 4A, B)". I don't really understand this seeming discrepancy. I just wonder if there is anything new that could be added.

Technical problems:

1) Line 65, Dhekne et al., 2021 should be 2018?

2) Figure 6 D, statistical significance is required. Or, the authors mean that there is an increasing trend but not statistically significant.

3) Figure 8 C, representative images would help if possible.

Reviewer #3:

Khan et al., is a Research Advance to a publication from the group in 2018. The work provides confirmation that a more common variant associated with PD in humans also results in a similar reduction in cilia frequency in cholinergic interneurons in the striatum. This was noted in one figure of the 2018 paper for a mouse knockin of the R1441C variant of LRRK2. In the current work they use both a knockin and a BAC overexpression of another LRRK2 variant, G2019S, to assess further the impact of the LRRK2 mutations on cilia in the striatum. They examine the frequency of cilia in ChAT+ striatal interneurons and astrocytes in mice with two different PD-associated mutations, and they also investigate SHH signaling in these cells. While the paper is an interesting advance over the prior work, I think some additional experiments and clarifications are needed to improve the work prior to publication.

A strength of the paper is that it further builds upon the prior work of this group on the mechanisms by which LRRK2 activating mutations suppress cilia by extending their findings to specific neurons within the brain. They show that cilia and ciliary signaling in cholinergic interneurons and astrocytes are affected by activating mutations in LRRK2. This is an important step in building the connection between the activation of the kinase, ciliary defects, and the actual neurodegenerative outcomes in patients.

However, a weakness of the paper is that the conclusions with regard to both phosphorylation of Rab10 in this in vivo context and SHH signaling extend a bit beyond the data and these gaps should be addressed.

Major points:

The LRRK2 inhibitor experiment in the PPM1H+/- mice in Figure 5 is confusing- why is this done such a short time beforehand here when in other experiments in Figure 4 the animals were fed the inhibitor for 2 weeks. It's also confusing that the text says "they strongly validate a link between LRRK2-Rab phosphorylation and ciliogenesis in specific brain cell types", however the inhibitor experiment doesn't show much change in RAB10 phosphorylation in the PPM1H mice +/- the inhibitor or even the PPM1H mice relative to WT. Some quantification here is necessary to better investigate these changes. And some work could also be done to better clarify the point the authors are trying to make here. More generally, the connection between Rab10 phosphorylation in vivo and the reduction in cilia frequency seems unclear. Is phosphorylation of RAB10 increased in the brain of the R1441C mice compared with WT? Only the knockin mice are shown, and I don't see this in the previous paper.

The Hh signaling data also needs some development and clarification. For the cholinergic neurons- are the overall levels of Gli1 affected? Could this be measured by RNAseq?

Another way to look at Hh signaling in the cholinergic neurons would be to look at Hh pathway components in cilia. SMO antibodies in particular often work well even in tissue. The authors could test whether SMO localization or intensity in the cilia of the cholinergic neurons is affected which would more directly address whether the cilia that are present are altered in their function as the authors posit.

The authors also state that reduced numbers of cilia in astrocytes of the R1441C mice leads to an overall reduction in Hh signaling in these cells. I understand they are inferring this from the fact that there are fewer ciliated astrocytes mice but it should also be shown directly.

https://doi.org/10.7554/eLife.67900.sa1

Author response

The manuscript has many strengths and the reviewers are generally quite positive but there are some remaining issues that need to be addressed, as outlined below:

1. It would make the case a bit stronger if the authors could look at the transcript levels of GDNF from the same RNA samples they used to analyze Gli1.

We thank the reviewers for this suggestion. As requested, we have now used RNAscope fluorescence in situ hybridization to measure GDNF transcripts in cholinergic neurons from dorsal striatal tissue of 5-month old wild type and G2019S LRRK2 mutant mice (New Figure 8). Our results show that GDNF transcripts are restricted primarily to cholinergic neurons of the dorsal striatum. Moreover, we find that in wild type animals, most GDNF transcripts are detected in ciliated cells. At first glance this would indicate that cilia-deficient LRRK2 mutant neurons would produce fewer GDNF transcripts. Surprisingly, however, in G2019S mutant mice, we detect a much greater proportion of GDNF transcripts in unciliated striatal cholinergic neurons compared with wild type neurons consistent with Hedgehog signaling dysregulation. We fail to detect a decrease in total GDNF transcripts, but Hedgehog dysregulation is very clear and seen in the cholinergic neurons and not in adjacent astrocytes.

The GDNF gene is a target of the Gli3 repressor (at least in the limb bud). Our data indicate that in the absence of cilia, cells lose cilia-dependent Gli3-repression of GDNF expression in G2019S striatal CIN. In previous work, Kottmann and colleagues (Gonzalez-Reyes et al., (2012)) noted a strong age dependence of GDNF loss, with the biggest effect at 12 months. Also, in that study, both dorsal and ventral striatal tissue was analyzed--here we have carried out single cell analyses of dorsal striatum only. Future experiments will determine whether older LRRK2 mutant mice show a further decrease in GDNF expression.

2. The work is of immense importance and experiments were well performed. However, more clarification in the text would be required if not more experiments, on the possible effect(s) of elevated levels of Gli1 transcript in the striatum. Additional work would allow the authors to get a sense of whether/how the changes in Gli levels that they report for the ciliated vs non ciliated translate to changes at the population level for each of the cell types. The authors suggest how they think it works, but it would be nice to actually show it. For example do the cholinergic neurons overall have reduced Hh output despite the fact that the cells that remain ciliated increase their response? This seems important in terms of understanding what is happening at the tissue level.

The reviewers ask us to clarify the consequences of changes in ciliary Hh signaling, and we agree this is important. In our new analyses, we quantify the contribution of ciliated and non ciliated cells to both total Gli1 and GDNF transcript production. Re-analysis of our data indicates that similar to what we see for GDNF, Gli1 response is strongly cilia dependent in wild type neurons but less cilia-dependent overall in mutant neurons. This is likely due to the same loss of cilia-dependent Gli3 repression seen for GDNF (point #1 above).

Interestingly we see a neuron-specific dysregulation that is not seen in adjacent astrocytes that retain cilia-dependent Gli1 responses.

3. Clarify the timing of the LRRK2 inhibitor experiments and why there was, and especially why there is not much of a change in Rab10 phosphorylation. Try to strengthen the link between Rab10 phosphorylation and reduced cilia.

Part of the reason it is hard to see decreases in Rab10 phosphorylation in brain is that there is very little unless one looks in PPM1H homozygous knock out brains (now shown in this revision). Four other reports have seen the same effect of apparent insensitivity of brain pRab10 to MLi treatment. The whole brain was analyzed by western blot and remember that the cholinergic interneurons that we study in the striatum represent only ~5% of the total cells present in that region; pRab10 changes or sensitivity to MLi-2 in that region cannot yet be monitored. Thus, current methods make it impossible to provide a direct connection between Rab phosphorylation and ciliation in cholinergic interneurons of the dorsal striatum. HOWEVER, this is why analysis of Rab-specific PPM1H phosphatase knockouts is so important--these animals phenocopy activating LRRK2 mutations, strongly supporting the idea that Rab phosphorylation is playing a critical role. In primary cultured astrocytes we see a clear correlation and this is also true for every other cell type analyzed. Future work will try to carry out mass spec determinations of pRab10 in small numbers of isolated, cholinergic striatal neurons.

In order to facilitate the revision, we have included all of the comments from the reviewers for a perspective but you should focus on the list above. We look forward to seeing your revised paper.

Reviewer #2:

While this study tests an important idea of how defect in ciliogenesis could lead to dopaminergic neuron loss based on the current knowledge of circuits between dopaminergic neurons in the substantia nigra and cholinergic interneurons in the striatum (Gonzalez-Reyes et al., (2012)), it has a missing component that should be addressed in order to establish this model:

It would be important to measure GDNF expression in the striatum. As the authors speculate that there is an overall decrease in Hh response due to less cilia, this statement will carry more weight if the authors show that there is an inhibition of GDNF expression. Ideally this would be done by measuring secreted GDNF. However, this may be technically very demanding. Alternatively, the authors could examine GDNF transcripts. Altered GDNF transcript/expression/release is more likely to cause damage to the dopaminergic neurons. As there is an elevated level of Gli1 transcripts in a smaller number of ciliated cells (cholinergic) in R1441C mice, it raises concerns about how much of DA loss might happen when there is an elevated level of Gli1. Addressing the question on GDNF could solve the issue.

We fail to detect loss of total GDNF transcripts in 5 month G2019S striatal cholinergic neurons but we see a shift in GDNF expression to non-ciliated cells, likely due to loss of cilia-dependent Gli3 repression of GDNF transcription (see above). Future experiments will explore this further in older animals that we do not currently have access to.

It would really build the study if you could examine GDNF expression, as is done in figure 6B of the Gonzalez-Reyes et al., (2012) manuscript. I do understand if this is too technically demanding. Alternatively, one could examine GDNF transcripts.

Note that the Gonzalez-Reyes study measured TOTAL striatal GDNF and the ventral striatum contributes significantly to this. We did try transcript detection and only see dysregulation in the mice available to us for this analysis.

Are there humans with PPM1H variants? NCBI's Clinvar database is a very good site to explore this.

At present we are not aware of any PD patients with PPM1H mutations. There are patients with PPM1M mutations, and we are exploring this further. Lack of mutation could be due to functional redundancy or embryonic lethality.

"Rab12 S105 phosphorylation also decreased in wild type (Figure 4C) and mutant (Figure 4A,B) brain (Figure 4). However, levels of pRab10 seemed unchanged (Figure 4A,B)". I don't really understand this seeming discrepancy. I just wonder if there is anything new that could be added.

Several other groups have also reported this (cited above). Remember that cilia are completely normal in many brain regions and changes in pRab10 in the rare cholinergic neurons of the dorsal striatum would not be detected in a whole brain western blot. Sadly we cannot yet stain the cells directly as the phosphoRab10 antibody doesn’t work.

Technical problems:

1) Line 65, Dhekne et al., 2021 should be 2018?

2021 is the correct reference that we forgot to include in the ref. List. Thanks for catching this!

2) Figure 6 D, statistical significance is required. Or, the authors mean that there is an increasing trend but not statistically significant.

We mean there is an increasing trend--Gli1 signal is only 1 or 2 dots and the animal to animal variability adds to our challenge at reaching significance. We have corrected the text accordingly.

3) Figure 8 C, representative images would help if possible.

Representative images were presented in (old) Figure 8A but we added many more as requested (New Figure 9).

Reviewer #3:

Major points:

The LRRK2 inhibitor experiment in the PPM1H+/- mice in Figure 5 is confusing- why is this done such a short time beforehand here when in other experiments in Figure 4 the animals were fed the inhibitor for 2 weeks.

We apologize for any confusion. We do not have large numbers of mutant animals. We were not able to feed the PPM1H mutant mice for two weeks with inhibitor; the two hour feeding was used to validate the pRab10 staining and the blots serve to document the genotypes. PPM1H-/- mutant animals (now added here) have higher levels of pRab10 than LRRK2 mutant tissues and in this case we do see MLi-2 sensitivity at 2 hours in whole brain. This is now a supplemental figure and we have clarified the text.

It's also confusing that the text says "they strongly validate a link between LRRK2-Rab phosphorylation and ciliogenesis in specific brain cell types", however the inhibitor experiment doesn't show much change in RAB10 phosphorylation in the PPM1H mice +/- the inhibitor or even the PPM1H mice relative to WT.

The text refers to the single cell phenotype analysis that is not captured in a whole brain western blot. The statement is based on PPM1H specificity for Rab GTPases changing ciliation in a rare neuronal subpopulation.

Some quantification here is necessary to better investigate these changes. And some work could also be done to better clarify the point the authors are trying to make here. More generally, the connection between Rab10 phosphorylation in vivo and the reduction in cilia frequency seems unclear. Is phosphorylation of RAB10 increased in the brain of the R1441C mice compared with WT? Only the knockin mice are shown, and I don't see this in the previous paper.

Please see discussion above. Whole brain was analyzed by western blot and remember that the cholinergic interneurons that we study in the striatum represent only ~5% of the total cells present in that region; pRab10 changes specifically in those cells cannot yet be monitored. Thus, current reagents make it impossible to provide a direct connection between Rab phosphorylation and ciliation in the cholinergic neurons of the striatum. However, in primary cultured astrocytes we see a clear correlation and this is also true for every other cultured cell type analyzed including patient derived G2019S IPs cells. Future work will try to carry out mass spec determinations of pRab10 in small numbers of cholinergic striatal neurons. That a Rab-specific phosphatase mutant has the same cilia loss phenotype as the hyperactive kinase supports the involvement of a phosphoRab.

The Hh signaling data also needs some development and clarification. For the cholinergic neurons- are the overall levels of Gli1 affected? Could this be measured by RNAseq?

See above.

Another way to look at Hh signaling in the cholinergic neurons would be to look at Hh pathway components in cilia. SMO antibodies in particular often work well even in tissue. The authors could test whether SMO localization or intensity in the cilia of the cholinergic neurons is affected which would more directly address whether the cilia that are present are altered in their function as the authors posit.

This is an important experiment for future work. To date our smoothened antibody from Rajat Rohatgi (considered among the best in the field) does not work well in this brain region at this resolution.

The authors also state that reduced numbers of cilia in astrocytes of the R1441C mice leads to an overall reduction in Hh signaling in these cells. I understand they are inferring this from the fact that there are fewer ciliated astrocytes mice but it should also be shown directly.

We have presented the recalculation of the data to show this directly (New Figure 8 C-E; New Figure 7E).

https://doi.org/10.7554/eLife.67900.sa2

Article and author information

Author details

  1. Shahzad S Khan

    1. Department of Biochemistry, Stanford University School of Medicine, Stanford, United States
    2. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Investigation, Validation, Visualization, Writing - original draft, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3962-0226
  2. Yuriko Sobu

    1. Department of Biochemistry, Stanford University School of Medicine, Stanford, United States
    2. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
    Contribution
    Conceptualization, Investigation, Methodology, Validation, Visualization, Writing - review and editing
    Competing interests
    No competing interests declared
  3. Herschel S Dhekne

    Department of Biochemistry, Stanford University School of Medicine, Stanford, United States
    Contribution
    Conceptualization, Data curation, Investigation, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2240-1230
  4. Francesca Tonelli

    1. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
    2. MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, United Kingdom
    Contribution
    Investigation, Project administration, Resources, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4600-6630
  5. Kerryn Berndsen

    1. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
    2. MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, United Kingdom
    Contribution
    Investigation, Validation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9353-7565
  6. Dario R Alessi

    1. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
    2. MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, United Kingdom
    Contribution
    Conceptualization, Data curation, Funding acquisition, Project administration, Supervision, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2140-9185
  7. Suzanne R Pfeffer

    1. Department of Biochemistry, Stanford University School of Medicine, Stanford, United States
    2. Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Supervision, Visualization, Writing - original draft, Writing - review and editing
    For correspondence
    pfeffer@stanford.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6462-984X

Funding

Michael J. Fox Foundation for Parkinson's Research (17298 & 6986)

  • Shahzad S Khan
  • Yuriko Sobu
  • Herschel S Dhekne
  • Francesca Tonelli
  • Kerryn Berndsen
  • Dario R Alessi
  • Suzanne R Pfeffer

Aligning Science Across Parkinson's (ASAP-000463)

  • Shahzad S Khan
  • Yuriko Sobu
  • Herschel S Dhekne
  • Francesca Tonelli
  • Kerryn Berndsen
  • Dario R Alessi
  • Suzanne R Pfeffer

National Institutes of Health (DK37332)

  • Suzanne R Pfeffer

Medical Research Council (MC_UU_12016/2)

  • Dario R Alessi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

This study was funded by the joint efforts of The Michael J Fox Foundation for Parkinson’s Research (MJFF) [17298 & 6,986 (SR P & DRA)] and Aligning Science Across Parkinson’s (ASAP) initiative. MJFF administers the grant (ASAP-000463, SRP & DRA) on behalf of ASAP and itself. Funds were also provided by the Medical Research Council [grant no. MC_UU_12016/2 (DRA)] and the pharmaceutical companies supporting the Division of Signal Transduction Therapy Unit (Boehringer-Ingelheim, GlaxoSmithKline, Merck KGaA (DRA)). For the purpose of open access, the authors have applied a CC-BY public copyright license to the Author Accepted Manuscript version arising from this submission. All primary data associated with each figure has been deposited in the Dryad repository and can be found at https://doi.org/10.5061/dryad76hdr7sxx. We are especially grateful to Drs. Rajat Rohatgi and Jennifer Kong for their critical input and Dr. Andreas Kottman for helpful discussion.

Ethics

All animal studies were performed in accordance with the Animals (Scientific Procedures) Act of 1986 and regulations set by the University of Dundee, the U.K. Home Office, and the Administrative Panel on Laboratory Animal Care at Stanford University.

Senior Editor

  1. Philip A Cole, Harvard Medical School, United States

Reviewing Editor

  1. Wade Harper, Harvard Medical School, United States

Reviewer

  1. Peter S McPherson, Montreal Neurological Institute, McGill University, Canada

Publication history

  1. Preprint posted: March 2, 2021 (view preprint)
  2. Received: March 2, 2021
  3. Accepted: October 17, 2021
  4. Accepted Manuscript published: October 18, 2021 (version 1)
  5. Version of Record published: October 27, 2021 (version 2)
  6. Version of Record updated: November 2, 2021 (version 3)

Copyright

© 2021, Khan et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 931
    Page views
  • 190
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cell Biology
    Herschel S Dhekne et al.

    Parkinson’s disease-associated LRRK2 kinase phosphorylates multiple Rab GTPases, including Rab8A and Rab10. We show here that LRRK2 kinase interferes with primary cilia formation in cultured cells, human LRRK2 G2019S iPS cells and in the cortex of LRRK2 R1441C mice. Rab10 phosphorylation strengthens its intrinsic ability to block ciliogenesis by enhancing binding to RILPL1. Importantly, the ability of LRRK2 to interfere with ciliogenesis requires both Rab10 and RILPL1 proteins. Pathogenic LRRK2 influences the ability of cells to respond to cilia-dependent, Hedgehog signaling as monitored by Gli1 transcriptional activation. Moreover, cholinergic neurons in the striatum of LRRK2 R1441C mice show decreased ciliation, which will decrease their ability to sense Sonic hedgehog in a neuro-protective circuit that supports dopaminergic neurons. These data reveal a molecular pathway for regulating cilia function that likely contributes to Parkinson’s disease-specific pathology.

    Editorial note: This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor's assessment is that all the issues have been addressed (see decision letter).

    1. Cell Biology
    Ian F Price et al.
    Research Article Updated

    The germ line produces gametes that transmit genetic and epigenetic information to the next generation. Maintenance of germ cells and development of gametes require germ granules—well-conserved membraneless and RNA-rich organelles. The composition of germ granules is elusive owing to their dynamic nature and their exclusive expression in the germ line. Using Caenorhabditis elegans germ granule, called P granule, as a model system, we employed a proximity-based labeling method in combination with mass spectrometry to comprehensively define its protein components. This set of experiments identified over 200 proteins, many of which contain intrinsically disordered regions (IDRs). An RNA interference-based screen identified factors that are essential for P granule assembly, notably EGGD-1 and EGGD-2, two putative LOTUS-domain proteins. Loss of eggd-1 and eggd-2 results in separation of P granules from the nuclear envelope, germline atrophy, and reduced fertility. We show that IDRs of EGGD-1 are required to anchor EGGD-1 to the nuclear periphery while its LOTUS domains are required to promote the perinuclear localization of P granules. Taken together, our work expands the repertoire of P granule constituents and provides new insights into the role of LOTUS-domain proteins in germ granule organization.